Inhibition of lung tumor growth in nude mice by siRNACD31 targeting PECAM-1

Oncology Letters

Volumn 8, Issue 1, 2014, Pages 33-40

  Ouyang, Jin Sheng ^a   Li, Yu Ping ^a   Chen, Cheng Shui ^a   Chen, Jun Jie ^a   Chen, Tong Ke ^a   Cai, Chang ^a   Yang, Li ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Carcinoma; Platelet endothelial adhesion molecule; Small interfering RNA; Tumor microenvironment; Vascular endothelial growth factor

Indexed keywords

CD31 ANTIGEN; LIPOPLEX; MESSENGER RNA; SMALL INTERFERING RNA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; HEMANGIOENDOTHELIOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; MALE; MOUSE; MTT ASSAY; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL INOCULATION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84901240264     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2091     Document Type: Article

References (41)

1. Kim ST, Uhm JE, Lee J, et al: Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 75: 82-88, 2012.
2. Cohen MH, Williams GA, Sridhara R, Chen G and Pazdur R: FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8: 303-306, 2003.
3. Perez-Soler R: The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin Cancer Res 10: 4238s-4240s, 2004.
4. de Gramont A and Van Cutsem E: Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 69 (Suppl 3): 46-56, 2005.
5. Park S, DiMaio TA, Scheef EA, Sorenson CM and Sheibani N: PECAM-1 regulates proangiogenic properties of endothelial cells through modulation of cell-cell and cell-matrix interactions. Am J Physiol Cell Physiol 299: C1468-C1484, 2010.
6. Woodfin A, Voisin MB and Nourshargh S: PECAM-1: a multi-functional molecule in inflammation and vascular biology. Arterioscler Thromb Vasc Biol 27: 2514-2523, 2007.
7. Bautch VL: VEGF-directed blood vessel patterning: from cells to organism. Cold Spring Harb Perspect Med 2: a006452, 2012.
8. Yang L, Guan H, He J, Zeng L, Yuan Z, Xu M, Zhang W, Wu X and Guan J: VEGF increases the proliferative capacity and eNOS/NO levels of endothelial progenitor cells through the calcineurin/NFAT signalling pathway. Cell Biol Int 36: 21-27, 2012.
9. Holash J, Davis S, Papadopoulos N, et al: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393-11398, 2002.
10. Ilan N and Madri JA: PECAM-1: old friend, new partners. Curr Opin Cell Biol 15: 515-524, 2003.
11. Watt SM, Gschmeissner SE and Bates PA: PECAM-1: its expression and function as a cell adhesion molecule on hemopoietic and endothelial cells. Leuk Lymphoma 17: 229-244, 1995.
12. Müller AM, Hermanns MI, Skrzynski C, Nesslinger M, Müller KM and Kirkpatrick CJ: Expression of the endothelial markers PECAM-1, vWf, and CD34 in vivo and in vitro. Exp Mol Pathol 72: 221-229, 2002.
13. DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinson CS, Wexler RS, Kerr JS, Garlanda C, Merwin JR, Madri JA and Albelda SM: Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 151: 671-677, 1997.
14. Zhou Z, Christofidou-Solomidou M, Garlanda C and DeLisser HM: Antibody against murine PECAM-1 inhibits tumor angiogenesis in mice. Angiogenesis 3: 181-188, 1999.
15. Tachezy M, Reichelt U, Melenberg T, Gebauer F, Izbicki JR and Kaifi JT: Angiogenesis index CD105 (endoglin)/CD31 (PECAM-1) as a predictive factor for invasion and proliferation in intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Histol Histopathol 25: 1239-1246, 2010.
16. Herbst RS, Ansari R, Bustin F, et al: Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 377: 1846-1854, 2011.
17. Prager GW, Lackner EM, Krauth MT, et al: Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab. Mol Oncol 4: 150-160, 2010.
18. Inai T, Mancuso M, Hashizume H, et al: Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165: 35-52, 2004.
19. Lagnien-Gaume V, Jehl J, Manzoni P, et al: Bevacizumab and lung cancer: eligible patients in daily practice. Rev Mal Respir 28: 25-31, 2011 (In French).
20. Soutschek J, Akinc A, Bramlage B, et al: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178, 2004.
21. Chien PY, Wang J, Carbonaro D, et al: Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther 12: 321-328, 2005.
22. Aleku M, Schulz P, Keil O, et al: Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 68: 9788-9798, 2008.
23. Czauderna F, Fechtner M, Dames S, et al: Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 31: 2705-2716, 2003.
24. Ouyang JS, Li YP, Li CY, et al: Mitochondrial ROS-K+ channel signaling pathway regulated secretion of human pulmonary artery endothelial cells. Free Radic Res 46: 1437-1445, 2012.
25. Bidwell GL III, Perkins E and Raucher D: A thermally targeted c-Myc inhibitory polypeptide inhibits breast tumor growth. Cancer Lett 319: 136-143, 2012.
26. Feng D, Nagy JA, Pyne K, Dvorak HF and Dvorak AM: Ultrastructural localization of platelet endothelial cell adhesion molecule (PECAM-1, CD31) in vascular endothelium. J Histochem Cytochem 52: 87-101, 2004.
27. Dimaio TA, Wang S, Huang Q, Scheef EA, Sorenson CM and Sheibani N: Attenuation of retinal vascular development and neovascularization in PECAM-1-deficient mice. Dev Biol 315: 72-88, 2008.
28. DeLisser H, Liu Y, Desprez PY, et al: Vascular endothelial platelet endothelial cell adhesion molecule 1 (PECAM-1) regulates advanced metastatic progression. Proc Natl Acad Sci USA 107: 18616-18621, 2010.
29. Delisser HM: Targeting PECAM-1 for anti-cancer therapy. Cancer Biol Ther 6: 121-122, 2007.
30. Aleku M, Fisch G, Möpert K, Keil O, Arnold W, Kaufmann J and Santel A: Intracellular localization of lipoplexed siRNA in vascular endothelial cells of different mouse tissues. Microvasc Res 76: 31-41, 2008.
31. Newman PJ and Newman DK: Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular cell biology. Arterioscler Thromb Vasc Biol 23: 953-964, 2003.
32. Ilan N, Mahooti S, Rimm DL and Madri JA: PECAM-1 (CD31) functions as a reservoir for and a modulator of tyrosine-phosphorylated beta-catenin. J Cell Sci 112: 3005-3014, 1999.
33. Wang Y and Sheibani N: PECAM-1 isoform-specific activation of MAPK/ERKs and small GTPases: implications in inflammation and angiogenesis. J Cell Biochem 98: 451-468, 2006.
34. Masuda M, Kogata N and Mochizuki N: Crucial roles of PECAM-1 in shear stress sensing of vascular endothelial cells. Nihon Yakurigaku Zasshi 124: 311-318, 2004 (In Japanese).
35. Fujiwara K, Masuda M, Osawa M, Kano Y and Katoh K: Is PECAM-1 a mechanoresponsive molecule? Cell Struct Funct 26: 11-17, 2001.
36. Limaye V, Li X, Hahn C, Xia P, Berndt MC, Vadas MA and Gamble JR: Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K/Akt and regulation of Bcl-2 family members. Blood 105: 3169-3177, 2005.
37. Bergom C, Goel R, Paddock C, Gao C, Newman DK, Matsuyama S and Newman PJ: The cell-adhesion and signaling molecule PECAM-1 is a molecular mediator of resistance to genotoxic chemotherapy. Cancer Biol Ther 5: 1699-1707, 2006.
38. Wu N, Kurosu T, Oshikawa G, Nagao T and Miura O: PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells. Int J Oncol 42: 419-428, 2013.
39. Masuda M, Osawa M, Shigematsu H, Harada N and Fujiwara K: Platelet endothelial cell adhesion molecule-1 is a major SH-PTP2 binding protein in vascular endothelial cells. FEBS Lett 408: 331-336, 1997.
40. Enciso JM, Gratzinger D, Camenisch TD, Canosa S, Pinter E and Madri JA: Elevated glucose inhibits VEGF-A-mediated endocardial cushion formation: modulation by PECAM-1 and MMP-2. J Cell Biol 160: 605-615, 2003.
41. Privratsky JR, Tilkens SB, Newman DK and Newman PJ: PECAM-1 dampens cytokine levels during LPS-induced endotoxemia by regulating leukocyte trafficking. Life Sci 90: 177-184, 2012.